Impact of biannual azithromycin on weight-for-age z-score among infants in the AVENIR cluster-randomised trial
These findings align with prior large-scale trials that demonstrated mortality benefits but no sustained effects of azithromycin on growth. Taken together, the results suggest that while azithromycin MDA reduces childhood mortality, it is unlikely to provide medium-term improvements in weight gain, highlighting the need for complementary nutritional interventions to address undernutrition in similar settings.
Authors
- Carolyn Brandt
- Catherine E. Oldenburg (ORCID: https://orcid.org/0000-0002-0763-399X)
- Ahmed M. Arzika (ORCID: https://orcid.org/0000-0001-7022-282X)
- Benjamin F. Arnold (ORCID: https://orcid.org/0000-0001-6105-7295)
- Almou Ibrahim
- Elodie Lebas (ORCID: https://orcid.org/0000-0001-5741-7155)
- Emily Colby
- Ramatou Maliki
- Travis C. Porco (ORCID: https://orcid.org/0000-0001-8813-3171)
- Thomas M. Lietman (ORCID: https://orcid.org/0000-0001-8216-0240)
- Alio M Karamba
- Bawa Aichatou
- Diallo Beidi
- Nasser Galo
- Nasser Harouna
- Moustapha Abarchi
- Zijun Liu
- Kieran Sunanda O’Brien (ORCID: https://orcid.org/0000-0002-1962-5321)
- Brittany F. Peterson (ORCID: https://orcid.org/0009-0008-8815-1642)
- Amza Abdou
- Sani Mahamadou
- I. Bello
Institutions
- University of California, San Francisco (US)
- San Francisco Foundation (US)
- Global Brain Health Institute (US)
- University of San Francisco (US)
Publication Details
- Journal
- BMJ Paediatrics Open
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1136/bmjpo-2025-004037
- Primary Topic
- Child Nutrition and Water Access
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bill and Melinda Gates Foundation
- Pfizer